Group One Trading
OVID icon

Group One Trading’s Ovid Therapeutics OVID Stock Holding History

Group One Trading’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Buy
18,663
+5,417
+41% +$14K ﹤0.01% 5400
2026
Q1 		$29.4K Buy
+13,246
New +$23.7K ﹤0.01% 5685
2025
Q4 		– Sell
-188,295
Closed -$290K – 8885
2025
Q3 		$245K Buy
+188,295
New +$163K ﹤0.01% 4457
2022
Q4 		– Sell
-1,532
Closed -$3K – 7872
2022
Q3 		$3K Sell
1,532
-36
-2% -$75 ﹤0.01% 7038
2022
Q2 		$3K Sell
1,568
-1,500
-49% -$3.63K ﹤0.01% 7318
2022
Q1 		$10K Sell
3,068
-9,838
-76% -$30.9K ﹤0.01% 7162
2021
Q4 		$41K Sell
12,906
-41,401
-76% -$142K ﹤0.01% 6478
2021
Q3 		$182K Sell
54,307
-11,394
-17% -$41.5K ﹤0.01% 5271
2021
Q2 		$257K Sell
65,701
-100,655
-61% -$397K ﹤0.01% 4956
2021
Q1 		$669K Buy
166,356
+100,721
+153% +$335K ﹤0.01% 3702
2020
Q4 		$152K Buy
65,635
+65,573
+105,763% +$306K ﹤0.01% 4268
2020
Q3 		$0 Sell
62
-8,338
-99% -$55.8K ﹤0.01% 6425
2020
Q2 		$62K Buy
+8,400
New +$39.3K ﹤0.01% 4225

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Group One Trading's OVID Position: Q2 2026 in Review

Group One Trading increased its Ovid Therapeutics (OVID) stake by 41% in Q2 2026, buying an estimated $14K and bringing the position to 18,663 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5400.

Group One Trading first reported a position in OVID in Q2 2020 and has held it in 13 quarters since. The position peaked at $669K in Q1 2021. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Group One Trading held 18,663 shares of Ovid Therapeutics worth $50.2K as of Q2 2026.
  • Group One Trading bought 5,417 Ovid Therapeutics shares in Q2 2026, an estimated $14K.
  • Ovid Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5400 holding.
  • Group One Trading first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Group One Trading's Ovid Therapeutics position peaked at $669K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.